Introduction:
The biosimilars market in China has been experiencing significant growth in recent years, driven by factors such as increasing healthcare expenditure, growing demand for affordable biologic drugs, and government initiatives to promote biosimilars development. According to a report by Grand View Research, the global biosimilars market is expected to reach $69.4 billion by 2026, with China emerging as a key player in the industry.
Top 10 Biosimilars Forums in China 2026:
1. China National Pharmaceutical Group Corporation (Sinopharm)
Sinopharm is a leading pharmaceutical company in China, with a strong presence in the biosimilars market. The company has been actively investing in biosimilars research and development, aiming to capture a significant share of the market.
2. Shanghai Fosun Pharmaceutical Group Co., Ltd.
Fosun Pharma is another key player in the Chinese biosimilars market, with a focus on developing high-quality and affordable biosimilar drugs. The company’s strong research capabilities and investment in innovation have helped it establish a strong foothold in the industry.
3. Qilu Pharmaceutical Co., Ltd.
Qilu Pharma is known for its biosimilars portfolio, including products such as rituximab and trastuzumab biosimilars. The company’s commitment to quality and affordability has made it a popular choice among healthcare providers and patients in China.
4. Jiangsu Hengrui Medicine Co., Ltd.
Hengrui Medicine is a major player in the biosimilars market, with a focus on developing biosimilar versions of blockbuster biologic drugs. The company’s strong research and development capabilities have helped it gain a competitive edge in the industry.
5. Beijing SL Pharmaceutical Co., Ltd.
SL Pharma is a key player in the biosimilars market, with a diverse portfolio of biosimilar drugs targeting various therapeutic areas. The company’s strong marketing and distribution network have helped it expand its reach across China.
6. 3SBio Inc.
3SBio is a leading biopharmaceutical company in China, with a strong focus on biosimilars development. The company’s biosimilar products have gained recognition for their quality and efficacy, driving growth in the Chinese biosimilars market.
7. Bio-Thera Solutions
Bio-Thera is a biotechnology company specializing in the development of biosimilar drugs. The company’s biosimilar portfolio includes products targeting cancer, autoimmune diseases, and other therapeutic areas. Bio-Thera’s commitment to innovation and quality has positioned it as a key player in the Chinese biosimilars market.
8. Innovent Biologics, Inc.
Innovent Biologics is a leading biopharmaceutical company in China, with a focus on developing biosimilar drugs for the treatment of cancer and autoimmune diseases. The company’s biosimilar products have gained regulatory approval and market acceptance, driving growth in the industry.
9. Henlius Biotech
Henlius is a biopharmaceutical company specializing in the development of biosimilar drugs. The company’s biosimilar portfolio includes products targeting oncology, autoimmune diseases, and other therapeutic areas. Henlius’s strong research and development capabilities have helped it establish a strong presence in the Chinese biosimilars market.
10. Mabpharm Limited
Mabpharm is a biopharmaceutical company focused on the development of biosimilar drugs. The company’s biosimilar portfolio includes products targeting cancer, autoimmune diseases, and other therapeutic areas. Mabpharm’s commitment to quality and affordability has made it a key player in the Chinese biosimilars market.
Insights:
The biosimilars market in China is expected to continue its rapid growth in the coming years, driven by factors such as increasing healthcare expenditure, growing demand for affordable biologic drugs, and government support for biosimilars development. According to a report by IQVIA, the biosimilars market in China is projected to reach $5.8 billion by 2026, with a CAGR of 25.6% from 2021 to 2026. As key players such as Sinopharm, Fosun Pharma, and Qilu Pharma continue to invest in research and development, the Chinese biosimilars market is poised for further expansion and innovation.
Related Analysis: View Previous Industry Report
